Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Cosyntropin

Cosyntropin: 2 brands, 2 generics; first approved Feb 21, 2008; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 2 ANDA applications approved.

Brands (NDA)
2
Generics (ANDA)
2
Listed patents
0
Presentations
4

Brand (NDA) products

Originator applications
  • NDA 016750
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.25MG/VIALINJECTABLEINJECTIONRxAP
  • COSYNTROPIN
    NDA 0220282008
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.25MG/ML (0.25MG/ML)SOLUTIONINTRAVENOUSDiscontinued

Generic (ANDA) products (2)

Abbreviated applications
  • COSYNTROPIN
    ANDA 2021472012
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.25MG/VIALINJECTABLEINJECTIONRxAP
  • COSYNTROPIN
    ANDA 0905742009
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.25MG/VIALINJECTABLEINJECTIONDiscontinued

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
18 yr 9 mo ago
Most recent approval
14 yr 4 mo ago

Approvals span 2008–2012 across 4 FDA applications.

Brand (NDA) 250%
Generic (ANDA) 250%

Cosyntropin: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.